Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 16, 2016

View Archived Issues

Plasma, urine and ligament tissue metabolites as potential biomarkers of ankylosing spondylitis

New PDE4 inhibitor blocks proinflammatory effects in plasma and CNS

MabVax Therapeutics reports progress in MVT-5873 and MVT-2163 programs

Resunab demonstrates clinical benefit in phase II trial in systemic sclerosis

Novel optimized mouse model of cyclophosphamide-induced bone marrow suppression

RXFP1 agonist ML-290 as a potential treatment for acute myocardial infarction

Full results of EUCLID trial of ticagrelor in peripheral artery disease trial divulged

Seegene and Institut Catala d'Oncologia collaborate on cancer diagnostics

CellMax-DNA Genetic Cancer Risk Test available in India

FDA gives fast track designation to Centrexion Therapeutics' CNTX-4975 for Morton's neuroma

Bristol-Myers Squibb and Enterome establish microbiome-focused immuno-oncology collaboration

AstraZeneca reviews highlights of third quarter 2016

OSE Immunotherapeutics and Selexis enter cancer immunotherapy, autoimmune disease collaboration

Otsuka announces pipeline developments of third quarter 2016

Aurora Diagnostics selected to provide Ventana PD-L1 Assay in U.S.

BLA submission for bevacizumab biosimilar ABP-215

Arena Pharmaceuticals patents 5-HT2C receptor agonists

Clearside Biomedical enrolls first patient in HULK study

ImmunoMet Therapeutics discloses OXPHOX inhibitors

Rhizen initiates phase I/IIa study of RP-3128 for asthma

H. Lundbeck describes PDE1 inhibitors

Bayer Pharma develops t-PA inhibitors

Medshine Discovery presents EGFR inhibitors

Modus Therapeutics gives update on phase II sevuparin study in sickle cell disease

ACADIA Pharmaceuticals begins phase II ADVANCE trial of pimavanserin

Albireo Pharma's A-4250 accepted into PRIME program

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...